SaMD and Digital Therapeutics: Reimbursement Models After Japan's FY2026 Overhaul | Policy & Market Intelligence

Description

List of Tables

Japan ran the world's first real test of whether digital therapeutics can live inside a national health-insurance system. Beginning with the reimbursement of CureApp SC for nicotine dependence in December 2020 - the first DTx covered by national insurance anywhere - Japan built a small but functioning category: hypertension treatment software followed in 2022, a game-based ADHD therapeutic from Shionogi and Akili was approved in February 2025, and CureApp's alcohol-dependence program gained approval in September 2025 with Sawai as distribution licensee. Then the FY2026 reimbursement overhaul rewrote the rules. The flat SaMD fee add-on that had anchored the category was replaced by outcomes-gated payment structures, and PMDA doubled its SaMD review capacity, signaling that the state expects more applications and intends to pay for results rather than novelty.

The overhaul cuts both ways. An outcomes-gated model rewards products with strong real-world evidence and punishes those without it, at precisely the moment when the global DTx industry is recovering from a credibility crisis: Pear Therapeutics' bankruptcy in 2023 and GAIA's insolvency in Germany reset investor expectations, while Germany's DiGA fast track continues to generate contested evidence on monetization. Whether Japan's new model becomes the template other payers copy, or another cautionary case, depends on design details that are still being interpreted.

This report decodes the FY2026 overhaul and maps what it means for SaMD and DTx strategy in Japan. It reconstructs the new fee architecture, explains the evidence and outcomes requirements, and profiles every reimbursed product and active developer - CureApp, Otsuka, Susmed, Shionogi, and their international counterparts from Akili and Click Therapeutics to Big Health, Kaia Health, and HelloBetter. Regulatory chapters cover the PMDA SaMD pathway, the two-track approval structure, and the interaction between approval and reimbursement timing. Comparative chapters examine Germany's DiGA, the US coverage landscape, and China's provincial clearances such as Tencent's cognitive-training software. The report answers the questions that decide go/no-go: what evidence package supports an outcomes-gated fee, how long the pathway takes, and which indications are commercially plausible under the new rules.

The audience is global SaMD and DTx companies, pharmaceutical digital-medicine teams, investors, and payers abroad watching Japan as a policy laboratory. The report functions as both a regulatory guide and a commercial reality check, with annual updates tracking each reimbursement cycle.

Scope and Coverage: The report covers SaMD and digital therapeutics regulation and reimbursement in Japan following the FY2026 overhaul, including the outcomes-gated fee structure, PMDA review capacity changes, and all reimbursed and pipeline products, with comparators from Germany's DiGA, the US, and China. It does not provide legal advice or predict individual product outcomes.

Report Highlights:

Full reconstruction of the FY2026 outcomes-gated SaMD reimbursement architecture
Profiles of every NHI-reimbursed Japanese DTx: CureApp SC, CureApp HT, CureApp AUD, and the Shionogi-Akili ADHD program
Developer landscape spanning CureApp, Otsuka, Susmed, Shionogi, Sawai, and international peers
PMDA SaMD review pathway and doubled review capacity analysis
Germany DiGA, US, and China comparator chapters including DiGA insolvency lessons
Evidence-package requirements for outcomes-gated fee eligibility

Product Code: JPH-061

Table of Content

1. Executive Summary

2. SaMD and Digital Therapeutics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

CureApp (JP) - NHI-reimbursed DTx products: CureApp SC (Dec 2020), CureApp HT (Sep 2022), CureApp AUD (Sep 2025)
Otsuka (JP) - digital medicine and DTx partnerships in CNS
Susmed (JP) - Japanese DTx developer in insomnia and other indications
Shionogi (JP) - ADHD game-based DTx approved Feb 2025, developed with Akili
Sawai (JP) - distribution licensee for CureApp AUD
Akili (US) - EndeavorRx and EndeavorOTC, pivoted to OTC model (2024)
Click Therapeutics (US) - prescription DTx pipeline across CNS and cardiometabolic
Big Health (US) - Sleepio and Daylight digital CBT programs
Voluntis (FR) - oncology DTx, acquired by Aptar Pharma (2021)
Pear Therapeutics (US) - bankruptcy (2023), reference case for DTx commercial risk
Kaia Health (DE/US) - DiGA-listed musculoskeletal DTx
HelloBetter (DE) - DiGA-listed mental-health DTx
GAIA (DE) - DiGA pioneer (velibra), insolvency (2023) as DiGA economics marker
Sidekick Health (DE) - DiGA-listed multi-condition DTx platform
Tencent (CN) - cognitive-training software cleared by Guangdong MPA (Jun 2025)

Product Code: JPH-061

List of Tables

Table 1. FY2026 SaMD reimbursement overhaul: structure of the outcomes-gated fee system
Table 2. Pre-2026 flat SaMD fee add-on design and its replacement
Table 3. PMDA SaMD review capacity expansion
Table 4. Two-track SaMD approval structure in Japan
Table 5. CureApp SC nicotine-dependence DTx reimbursement history (December 2020)
Table 6. CureApp HT hypertension DTx reimbursement history (September 2022)
Table 7. CureApp AUD alcohol-dependence DTx approval (September 2025)
Table 8. Sawai distribution license structure for CureApp AUD
Table 9. Shionogi-Akili game-based ADHD DTx approval (February 2025)
Table 10. Otsuka digital medicine and CNS DTx partnership portfolio
Table 11. Susmed DTx pipeline in insomnia and other indications
Table 12. Akili EndeavorRx and EndeavorOTC and the 2024 OTC pivot
Table 13. Click Therapeutics prescription DTx pipeline across CNS and cardiometabolic
Table 14. Big Health Sleepio and Daylight digital CBT programs
Table 15. Voluntis oncology DTx and the Aptar Pharma acquisition (2021)
Table 16. Pear Therapeutics bankruptcy (2023) as a DTx commercial risk case
Table 17. Kaia Health DiGA-listed musculoskeletal DTx
Table 18. HelloBetter DiGA-listed mental-health DTx
Table 19. GAIA DiGA pioneer history and 2023 insolvency
Table 20. Sidekick Health DiGA-listed multi-condition platform
Table 21. Tencent cognitive-training software Guangdong clearance (June 2025)
Table 22. Outcomes evidence requirements under the FY2026 fee rules
Table 23. Real-world data collection obligations for reimbursed DTx
Table 24. Indication categories with active DTx development in Japan
Table 25. Prescription and dispensing workflow for reimbursed DTx
Table 26. Physician fee items associated with DTx prescribing
Table 27. Medical institution requirements for DTx provision
Table 28. SaMD classification rules under PMDA guidance
Table 29. Precedent review timelines for approved Japanese DTx
Table 30. Foreign-manufacturer accreditation requirements for SaMD
Table 31. Clinical evidence standards for DTx approval
Table 32. Interaction between approval timing and reimbursement listing
Table 33. Germany DiGA fast-track structure and evidence rules
Table 34. US DTx coverage landscape across payers
Table 35. China provincial DTx clearance landscape
Table 36. Comparative reimbursement design matrix across Japan, Germany, and the US
Table 37. DTx pricing formation under outcomes-gated rules
Table 38. Patient-engagement and adherence evidence in reimbursed products
Table 39. Distribution channel options for DTx in Japan
Table 40. Pharmaceutical partnership models for DTx commercialization
Table 41. Investment and funding landscape for Japanese DTx developers
Table 42. Academic society positions on digital therapeutics
Table 43. Data privacy and security requirements for SaMD
Table 44. Post-market surveillance obligations for reimbursed DTx
Table 45. Pipeline map of DTx candidates approaching PMDA submission
Table 46. Indication attractiveness framework under outcomes-gated payment
Table 47. Entry sequencing for foreign DTx companies into Japan
Table 48. Scenario framework for the FY2028 reimbursement revision
Table 49. Stakeholder map for SaMD reimbursement policy
Table 50. Report methodology and update schedule

List of Figures

Figure 1. FY2026 outcomes-gated SaMD fee architecture
Figure 2. Evolution of Japanese SaMD reimbursement design
Figure 3. PMDA SaMD review pathway flowchart
Figure 4. Two-track approval structure diagram
Figure 5. CureApp reimbursed product family timeline
Figure 6. CureApp SC clinical and reimbursement pathway
Figure 7. CureApp HT clinical and reimbursement pathway
Figure 8. CureApp AUD approval and Sawai distribution structure
Figure 9. Shionogi-Akili ADHD DTx development and approval pathway
Figure 10. Otsuka digital medicine partnership map
Figure 11. Susmed DTx pipeline structure
Figure 12. Akili business model evolution to OTC
Figure 13. Click Therapeutics pipeline map
Figure 14. Big Health digital CBT program structure
Figure 15. Pear Therapeutics trajectory as a commercial risk case
Figure 16. German DiGA-listed product landscape including GAIA and HelloBetter
Figure 17. Tencent cognitive-training clearance in China
Figure 18. Outcomes evidence package anatomy
Figure 19. Real-world data obligations for reimbursed DTx
Figure 20. Indication map of active Japanese DTx development
Figure 21. Prescription workflow for reimbursed DTx
Figure 22. Physician fee item structure around DTx prescribing
Figure 23. Medical institution readiness requirements
Figure 24. SaMD classification decision logic
Figure 25. Approval-to-reimbursement sequencing diagram
Figure 26. Foreign-manufacturer accreditation pathway
Figure 27. Clinical evidence standard framework for DTx
Figure 28. Germany DiGA fast-track flow
Figure 29. US DTx coverage pathway map
Figure 30. China provincial clearance map
Figure 31. Comparative reimbursement design matrix
Figure 32. Outcomes-gated pricing formation logic
Figure 33. Adherence evidence structure in reimbursed products
Figure 34. DTx distribution channel options
Figure 35. Pharmaceutical partnership archetypes for DTx
Figure 36. Japanese DTx funding landscape
Figure 37. Academic society engagement map
Figure 38. Data privacy architecture for SaMD
Figure 39. Post-market surveillance flow for DTx
Figure 40. Pipeline map toward PMDA submission
Figure 41. Indication attractiveness scoring framework
Figure 42. Foreign DTx entry sequencing options
Figure 43. Scenario tree toward the FY2028 revision
Figure 44. Stakeholder influence map in SaMD policy
Figure 45. Fee schedule mechanics under the new rules
Figure 46. Patient journey through a reimbursed DTx episode
Figure 47. Comparative regulatory status matrix for DTx categories
Figure 48. Commercial readiness checklist for Japan DTx launch
Figure 49. Risk map for DTx developers under outcomes-gated payment
Figure 50. Report scope, method, and annual update design

SaMD and Digital Therapeutics: Reimbursement Models After Japan's FY2026 Overhaul | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. SaMD and Digital Therapeutics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures